Hitomi Ozawa-Umeta - JoVE Visualize

Showing results (1-10 of 3) with videos related to

Pageof 1

Sort By:

Cancer Science|March 13, 2020

Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivoHitomi Ozawa-Umeta, Atsuhiro Kishimoto, Atsushi Imaizumi, et al.

Journal of Nutritional Science and Vitaminology|August 31, 2025

Enhancing Cannabidiol Bioavailability: Development and Evaluation of an Amorphous Cannabidiol Powder FormulationHiroki Aoyama, Tatsuya Ogawa, Hitomi Ozawa-Umeta, et al.

European Journal of Pharmacology|October 13, 2022

Pharmacologic characterization of TBP1901, a prodrug form of aglycone curcumin, and CRISPR-Cas9 screen for therapeutic targets of aglycone curcuminTomoyuki Abe, Yoshihito Horisawa, Osamu Kikuchi, et al.

Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:

Pageof 1

Cancer Science|March 13, 2020

Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivoHitomi Ozawa-Umeta, Atsuhiro Kishimoto, Atsushi Imaizumi, et al.

Journal of Nutritional Science and Vitaminology|August 31, 2025

Enhancing Cannabidiol Bioavailability: Development and Evaluation of an Amorphous Cannabidiol Powder FormulationHiroki Aoyama, Tatsuya Ogawa, Hitomi Ozawa-Umeta, et al.

European Journal of Pharmacology|October 13, 2022

Pharmacologic characterization of TBP1901, a prodrug form of aglycone curcumin, and CRISPR-Cas9 screen for therapeutic targets of aglycone curcuminTomoyuki Abe, Yoshihito Horisawa, Osamu Kikuchi, et al.

Pageof 1